Comparative Pharmacology
Head-to-head clinical analysis: FRINDOVYX versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FRINDOVYX versus LUSEDRA.
FRINDOVYX vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Frindovyx is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
10 mg orally once daily.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe impairment (CrCl <30 mL/min).
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 30% recovered as inactive metabolites in urine. Fecal/biliary elimination constitutes the remaining 10%.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic